PA
MRVI icon

Parallel Advisors’s Maravai LifeSciences MRVI Stock Holding History

Parallel Advisors’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.68K Hold
269
– – ﹤0.01% 3561
2026
Q1 		$761 Sell
269
-3,516
-93% -$11.9K ﹤0.01% 3584
2025
Q4 		$12.3K Hold
3,785
– – ﹤0.01% 2520
2025
Q3 		$10.9K Buy
+3,785
New +$9.66K ﹤0.01% 2507
2025
Q2 		– Sell
-787
Closed -$1.74K – 3655
2025
Q1 		$1.74K Sell
787
-213
-21% -$842 ﹤0.01% 3011
2024
Q4 		$5.45K Sell
1,000
-432
-30% -$2.78K ﹤0.01% 2610
2024
Q3 		$11.9K Sell
1,432
-89
-6% -$769 ﹤0.01% 2332
2024
Q2 		$10.9K Buy
1,521
+71
+5% +$613 ﹤0.01% 2280
2024
Q1 		$12.6K Sell
1,450
-560
-28% -$3.79K ﹤0.01% 2208
2023
Q4 		$13.2K Buy
2,010
+902
+81% +$5.83K ﹤0.01% 2169
2023
Q3 		$11.1K Buy
1,108
+978
+752% +$10.7K ﹤0.01% 2144
2023
Q2 		$1.62K Sell
130
-907
-87% -$12.2K ﹤0.01% 2813
2023
Q1 		$14.5K Buy
1,037
+163
+19% +$2.34K ﹤0.01% 1974
2022
Q4 		$12.5K Buy
874
+727
+495% +$11.4K ﹤0.01% 1942
2022
Q3 		$4K Buy
+147
New +$3.69K ﹤0.01% 2394

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Parallel Advisors's MRVI Position: Q2 2026 in Review

Parallel Advisors held its Maravai LifeSciences (MRVI) position steady in Q2 2026 at 269 shares worth $1.68K. The position accounts for ﹤0.01% of the portfolio, ranked #3561.

Parallel Advisors first reported a position in MRVI in Q3 2022 and has held it in 15 quarters since. The position peaked at $14.5K in Q1 2023. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • Parallel Advisors held 269 shares of Maravai LifeSciences worth $1.68K as of Q2 2026.
  • Parallel Advisors left its Maravai LifeSciences share count unchanged in Q2 2026.
  • Maravai LifeSciences made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3561 holding.
  • Parallel Advisors first reported a position in Maravai LifeSciences in Q3 2022 and has held it in 15 quarters since.
  • Parallel Advisors's Maravai LifeSciences position peaked at $14.5K in Q1 2023.
  • 178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.